Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer

NCT01064310 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

169

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: pazopanib
DRUG: sunitinib

Sponsor

Novartis Pharmaceuticals